← All trials
NCT03784014
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2019
- Primary completion
- Mar 31, 2022
- Completion date
- Mar 31, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 960
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Institut National de la Santé Et de la Recherche Médicale, FranceLead sponsor
- Institut BergoniéCollaborator
- Institut BergoniéOverall official - principal investigator
- Hôpital Européen Georges-PompidouCollaborator
- Commissariat A L'energie AtomiqueCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.